Bar Harbor Trust Services cut its position in Becton, Dickinson and Company (NYSE:BDX) by 0.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,862 shares of the medical instruments supplier’s stock after selling 10 shares during the period. Becton, Dickinson and accounts for 3.4% of Bar Harbor Trust Services’ investment portfolio, making the stock its 12th largest holding. Bar Harbor Trust Services’ holdings in Becton, Dickinson and were worth $6,412,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in BDX. North Star Investment Management Corp. increased its position in shares of Becton, Dickinson and by 3.4% in the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 18 shares during the last quarter. Almanack Investment Partners LLC. purchased a new stake in shares of Becton, Dickinson and in the 1st quarter valued at approximately $105,000. Parkside Financial Bank & Trust increased its position in shares of Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 9 shares during the last quarter. QCI Asset Management Inc. NY increased its position in shares of Becton, Dickinson and by 9.2% in the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 60 shares during the last quarter. Finally, Financial Architects Inc increased its position in shares of Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the last quarter. 87.43% of the stock is currently owned by institutional investors.

Shares of Becton, Dickinson and Company (BDX) opened at 195.34 on Friday. The company’s 50-day moving average is $199.43 and its 200-day moving average is $191.33. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm has a market cap of $44.45 billion, a PE ratio of 56.57 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the previous year, the firm earned $2.35 earnings per share. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. Analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.49%. Becton, Dickinson and’s payout ratio is 83.43%.

WARNING: This report was originally posted by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/16/becton-dickinson-and-company-bdx-holdings-lowered-by-bar-harbor-trust-services.html.

In other news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Ribo Alberto Mas sold 7,463 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the transaction, the executive vice president now owns 29,323 shares of the company’s stock, valued at approximately $5,905,945.43. The disclosure for this sale can be found here. In the last quarter, insiders have sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is owned by insiders.

BDX has been the topic of a number of recent analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research report on Tuesday. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Cowen and Company reaffirmed a “buy” rating and issued a $230.00 target price on shares of Becton, Dickinson and in a research report on Monday, August 14th. Barclays PLC reaffirmed an “equal weight” rating and issued a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $196.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.